Showcasing Phase II & III Readouts of Luvelta & Outlining Predications for Future ADC Innovation (ADC London 2025) - Mar 5, 2025 - Pres time: Mar 4, 2025; 09:30 AM - 10:00 AM; "Synopsis • Sharing an update on clinical data for Luvelta targeting FRα in recurrent, platinum-resistant ovarian cancer, endometrial cancer, and AML • Reflecting on the development and main drivers of successes in the ADC field • Exploring future directions of the ADC field across dual payload conjugates, including Immune activating payload ADCs"
P2 data • Endometrial Cancer • Oncology • Ovarian Cancer • Solid Tumor • FOLR1
|